Tag: Osmr

Vixarelimab is being investigated for conditions involving itch and inflammation. A key aspect is understanding the unique dual mechanism of action of Vixarelimab.

According to a 2023 study published in *The Lancet*, the investigational human monoclonal antibody **vixarelimab** showed rapid and clinically meaningful reductions in pruritus in patients with moderate-to-severe prurigo nodularis. This promising therapy targets a dual-signaling pathway to address both the intense itch and the skin nodules associated with the condition.